Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Convertible Debt: 2022

  • bioAffinity Technologies' Convertible Debt was N/A to $325,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $325,000, marking a year-over-year change of. This contributed to the annual value of $325,000 for FY2022, which is N/A change from last year.
  • Latest data reveals that bioAffinity Technologies reported Convertible Debt of $325,000 as of Q4 2022, which was down 87.50% from $2.6 million recorded in Q3 2022.
  • bioAffinity Technologies' 5-year Convertible Debt high stood at $2.6 million for Q3 2022, and its period low was $325,000 during Q4 2022.
  • Over the past 1 years, bioAffinity Technologies' median Convertible Debt value was $1.5 million (recorded in 2022), while the average stood at $1.5 million.